期刊文献+

艾塞那肽治疗肥胖2型糖尿病疗效观察 被引量:8

艾塞那肽治疗肥胖2型糖尿病疗效观察
暂未订购
导出
摘要 目的:观察艾塞那肽治疗2型糖尿病的疗效。方法:将2型糖尿病患者100例随机分为治疗组50例和对照组50例。在常规服用二甲双胍基础上,治疗组予艾塞那肽皮下注射,对照组予胰岛素(诺和灵50R)皮下注射,观察疗效和不良反应。结果:艾塞那肽组的血糖控制和胰岛素组相比无显著差异,两组空腹血糖下降幅度相似,艾塞那肽对餐后血糖的控制更好;艾塞那肽对肥胖患者有控制体重增加,减轻体重作用,降低血脂,左心室内径缩小。两组均未发生严重不良反应。结论:艾塞那肽治疗2型糖尿病能有效控制血糖,并有效控制体重增加。 Objective:Concept the Cha Aise that peptide efficacy of the treatment of type 2 diabetes:Type 2 diabetes patients were randomly divided into a treatment group of 50 patients,50 patients were treated.On the basis of conventional metformin treatment group to exenatide subcutaneously to insulin(Novolin 50R)subcutaneous injection of the control group,observation of efficacy and adverse reactions.Result:a the exenatide group of glycemic control and insulin groups showed no significant difference in the two sets of fasting blood glucose decline similar exenatide better postprandial glucose control;exenatide on weight control in obese patients increase the weight loss effect,lowering blood lipids,left ventricular diameter narrowing.The two groups were not serious adverse reactions.Conclusions:Exenatide treatment of type 2 diabetes can effectively control blood sugar,and effectively control weight gain.
作者 庞敏 张红军
出处 《中国社区医师(医学专业)》 2013年第10期143-144,共2页
关键词 艾塞那肽 2型糖尿病 疗效血糖 体重 血脂 左心室内径 Exenatide II diabetes efficacy blood sugar weight lipids left ventricular internal diameter
  • 相关文献

参考文献3

二级参考文献33

  • 1广东省糖尿病流行病学调查协作组.腰围/身高比值:预测糖尿病和高血压的有效的腹型肥胖指标[J].中华内分泌代谢杂志,2004,20(3):272-275. 被引量:163
  • 2王辉,姜燕,张凤岭,孙卓祥.胰岛素抵抗与动脉粥样硬化的相关性研究[J].济宁医学院学报,2005,28(3):65-65. 被引量:1
  • 3Dov A, Abramovitch E, Warwar N, et al. Diminished phospho-diesterase-SB potentiates biphasic insulin response to glucose. Endocrinology, 2008,149:741-748.
  • 4Yaekura K, Julyan R, Wicksteed BL, et al. Insulin secretory deficiency and glucose intolerance in Rab3A null mice. J Biol Chem, 2003,278,9715-9721.
  • 5Doyte M, Egan JM. Pharmacological agents that directly modulate insulin secretion. Pharmacol Rev, 2003,55:105-131.
  • 6Park H, Dong X, Fisher TL, et al. Exendin-4 uses Irs 2 signaling to mediate pancreatic β cell growth and function. J Biol Chem, 2006, 281:1159-1168.
  • 7Knoch KP, Meisteffeld R, Kersting S, et al. cAMP-dependent phosphorylation of PTB1 promotes the expression of insulin secretory granule proteins in β cells. Cell Metab, 2006,3:123-134.
  • 8Buteau J, Spatz ML, Accili D. Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic β-cell mass. Diabetes, 2006,55 : 1190-1196.
  • 9De Heer J, Hoist JJ. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes, 2007,56:438-443.
  • 10MacDonald PE, Wheeler MB. Vohage-dependent K^+ channels in pancreatic β cells: role, regulation and potential as therapeutic targets. Diabetologia, 2003,46 : 1046-1062.

共引文献47

同被引文献57

引证文献8

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部